Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLK1 Recombinant Protein (Kinase Domain / Polo-Box Domain) High purity (>90%), GST/His-tagged. Sequence Verified. Theoretical MW confirmed by SDS-PAGE. |
View PLK1 Products |
| Gene Delivery | PLK1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View PLK1 Products |
| Benchmark Ab | Anti-PLK1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View PLK1 Products |
| Validator | PLK1 siRNA Set For knockdown verification and target specificity validation. |
View PLK1 Products |
| Related Target A | PLK2 Essential for subfamily counter-screening to avoid off-target toxicity. |
View PLK2 Products |
| Related Target B | PLK4 Key regulator of centriole duplication; critical counter-screening target for PLK selectivity. |
View PLK4 Products |
| Related Target C | WEE1 Synergistic cell cycle regulator; co-inhibition enhances mitotic catastrophe in TP53-deficient tumors. |
View WEE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (PLK2/3/4) | Kinase Panel Proteins strictly verified by mass spectrometry and sequence analysis. |
| Domain-specific targeting (Kinase Domain vs. PBD) | Truncated and domain-specific recombinant proteins (PBD domain, Kinase domain) available. |
| Lack of Controls | Clinical benchmark antibodies and verified positive control reagents included. |
| False Positives in Phenotypic Screening | Validated siRNA sets included for target-specific knockdown comparisons. |
Live PLK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PLK1 therapeutics is intensifying, with major players shifting focus from traditional ATP-competitive small molecule inhibitors (SMIs) to more selective modalities such as Polo-Box Domain (PBD) inhibitors, PROTACs (proteolysis targeting chimeras), and RNA interference (RNAi). As first-generation pan-PLK inhibitors faced dose-limiting toxicities (primarily myelosuppression), the next wave of R&D is targeting highly selective PLK1 degradation and synergistic combination regimens to maximize therapeutic index.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (SMI) | Cardiff Oncology, Boehringer Ingelheim | Colorectal Cancer, Prostate Cancer, AML | Selectivity Assay (Need PLK1 vs PLK2/4 Mutant & WT Proteins) |
| PROTAC / Degrader | Academic Spin-offs, Biotech Startups | Solid Tumors, Hematological Malignancies | Degradation Kinetics (Need High-Purity PLK1 for SPR/FP Binding Assays) |
| RNAi / siRNA | Alnylam, Silence Therapeutics (Preclinical) | Hepatic and Non-hepatic Tumors | Knockdown Validation (Need Sequence-Verified siRNA and Lentivirus Controls) |